The fight for our genes heads to court
By Editorial,
San Francisco Chronicle [cites Marcy Darnovksy]
| 05. 23. 2009
Twenty percent of your body belongs to someone else.
Don't believe us? Check the U.S. Patent Office. Twenty percent of all human genes have been patented, mostly by private companies and research institutions. These patents are crippling the ability of scientists to study diseases and restricting patients from getting the information they need to make important medical decisions about their health.
This month, six breast cancer patients filed suit against Myriad Genetics, a company that owns both the patent on two genes that are associated with an increased risk for breast cancer and ovarian cancer and the patent on testing to measure those risks. Some of these women are suing because they can't afford the $3,000 fee Myriad charges to determine their risk for breast or ovarian cancer. Some of them are suing because, thanks to Myriad's patent, they can't get second opinions about whether they should have their breasts or ovaries removed - no one else is allowed to perform another test for them.
All of them are suing because they did not, and should not, expect to have...
Related Articles
By Jim Thomas, Scan the Horizon | 11.19.2024
It’s the wee hours of 2nd November 2024 in Cali, Colombia. In a large UN negotiating hall Colombian Environment Minister Susana Muhamed has slammed down the gavel on a decision that should send a jolt through the AI policy world. ...
By Ewan Bolton, The Telegraph | 11.12.2024
Fertility agencies offering embryo selection for IVF and surrogacy have been accused of promoting eugenics and misleading consumers about the power of genetic screening.
Some American clinics claim they can “rank” embryos for IVF using Preimplantation Genetic Testing for Polygenic...
By Ned Pagliarulo, BioPharmaDive | 11.05.2024
A medicine built around a more precise form of CRISPR gene editing appeared to work as designed in its first clinical trial test, developer Beam Therapeutics said Tuesday. But the death of a trial participant could renew concerns about an older...
By Fyodor Urnov, The CRIPSR Journal | 10.18.2024
The field of clinical gene editing has a bona fide crisis on its hands—a crisis that has to, and can be, promptly resolved.
An outside observer of our field might be surprised by this and say—what crisis? The first...